|
PTBP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69753100465186E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.2381984326737E-11 |
| Normal-vs-Stage2 |
1.3395999998167E-07 |
| Normal-vs-Stage3 |
4.26214619153598E-13 |
| Normal-vs-Stage4 |
1.53310000250428E-08 |
| Stage1-vs-Stage2 |
6.339200E-01 |
| Stage1-vs-Stage3 |
6.390500E-02 |
| Stage1-vs-Stage4 |
1.412800E-01 |
| Stage2-vs-Stage3 |
4.152200E-01 |
| Stage2-vs-Stage4 |
4.763000E-01 |
| Stage3-vs-Stage4 |
9.113000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.05089287166993E-13 |
| Normal-vs-AfricanAmerican |
9.415000E-04 |
| Normal-vs-Asian |
4.87670000048901E-07 |
| Caucasian-vs-AfricanAmerican |
2.055800E-01 |
| Caucasian-vs-Asian |
2.922000E-01 |
| AfricanAmerican-vs-Asian |
6.436200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.63609999998182E-07 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
3.045700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.11430872809615E-12 |
| Normal-vs-Age(41-60Yrs) |
5.80490100432485E-11 |
| Normal-vs-Age(61-80Yrs) |
2.86099999247114E-09 |
| Normal-vs-Age(81-100Yrs) |
3.495600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.937400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.068200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.775800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.998200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.211000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.079600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.2341000000844E-07 |
| Classical-VS-Follicular |
4.506600E-01 |
| Classical-VS-Other |
6.346400E-01 |
| Classical-VS-Normal |
2.20401474848586E-12 |
| Tall-VS-Follicular |
4.24049999999676E-05 |
| Tall-VS-Other |
8.138100E-02 |
| Tall-VS-Normal |
1.62758695410048E-12 |
| Follicular-VS-Other |
9.073800E-01 |
| Follicular-VS-Normal |
4.89120000002341E-06 |
| Other-VS-Normal |
3.048000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.77475828372553E-15 |
| Normal-vs-N1 |
2.447900E-04 |
| N0-vs-N1 |
1.537840E-01 |
|
|
